Tagged with BioTech

Bulgaria Krassimira Chemishanska, country director at Amgen Bulgaria, showcases the role of innovative players in the country, the importance of moving towards a value-based assessment system, and how Amgen has performed since its entrance to the Bulgarian market back in 2009. You opened the Bulgarian affiliate back in 2009. How challenging…

Canada Andrew Casey, President and CEO of BIOTECanada, the national biotech association, provides an update on the Canadian biotech landscape, the strength of the Canadian R&D ecosystem, the growing investor community (both Canadian and foreign) looking to Canada as an untapped land of opportunities, and his hope to position Canada as…

Tunisia Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities as general manager, the increasing importance of building new partnerships between the private and public sectors, and the Institute’s ambition…

Canada Peter Brenders, general manager of Sanofi Genzyme Canada, highlights the strategic significance of the Canadian affiliate, which has seen double-digit growth every quarter for the past five and a half years; the challenges it faces within Canada’s market access environment; and the personal motivation driving him after three decades in…

Tunisia The long-awaited conference marking the launch of the company cluster of Sidi Thabet (a city in the governorate of Ariana, 20 minutes from Tunis airport) took place on September 28th 2017 at the Tunis export centre (CEPEX) and revolved around the theme: “Sidi Thabet BioTechpole: serving innovation in the pharmaceutical…

Tunisia Hatem Hachicha is Pfizer’s former manager for Tunisia, Libya and French-speaking African countries. He believes Tunisia’s pharmaceutical industry development will be achieved through internationalization and a shift towards biosimilars drugs. Co-founder of SEPHIRE and an active member of the Tunisian healthcare community, he stresses that one of the challenges in…

Austria Dr. Daniel Wallerstorfer, CEO and founder of Novogenia, a vibrant Austrian genetics company, discusses founding his own company and the innovative services Novogenia provides to ensure genetics are a staple part of global preventative measures. He also provides an insight into the future of genetic analysis and the positive overall…

Colombia Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors.  Could you introduce our readers to the…

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…

Austria Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing as Austria capitalizes on its ideal central European location and impressively educated workforce. “From a biotech perspective, [Austria] has a…

Austria Arnoldas Doviltis, general manager of Ferring Austria, a research-driven Swiss biopharmaceutical company, elaborates on the autonomous nature of local Ferring affiliates and how this allows a tailored approach to conduct Austrian operations. Furthermore, he provides an insight into the peculiarities of market access within Austria compared to other European nations…

Austria Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the services and one stop shop approach they provide for their three main focuses; Big Pharma, small to mid-size biotechs and…